title: Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology.
abstract: Prostanoids, consisting of prostaglandins and thromboxane, are cyclooxygenase metabolites of arachidonic acid released in various pathophysiological conditions which exert a range of actions mediated through their respective receptors expressed on target cells. Although it has been difficult to analyze the physiological role of prostanoids, recent developments in both the disruption of the respective gene and receptor selective compounds have enabled us to investigate the physiological roles for each receptor. It has been demonstrated that each prostanoid receptor has multiple functions, and that their expression is regulated in a context-dependent manner that sometimes results in opposite, excitatory and inhibitory, outcomes. The balance of prostanoid production and receptor expression has been revealed to be important for homeostasis of the human body. Here, we review new findings on the roles of prostanoids in allergic and immune diseases, focusing on contact dermatitis, atopic dermatitis, asthma, rheumatoid arthritis, and encephalomyelitis, and also discuss the clinical potentials of receptor-selective drugs.
authors.affiliation: Department of Dermatology and Center for Innovation in Immunoregulative Technology and Therapeutics, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Honda
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Tokura
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Miyachi
authors.forename: Kenji
authors.initials: K
authors.lastname: Kabashima
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D015195:Drug Design; D004679:Encephalomyelitis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D007114:Immunization; D058990:Molecular Targeted Therapy; D011448:Prostaglandin Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D011453:Prostaglandins / Q000502:physiology*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013931:Thromboxanes / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D018926:Anti-Allergic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013931:Thromboxanes